Reactive airway disease

CMS Grants Transitional Pass-Through (TPT) Payment for Ambu’s aScope 5 Broncho HD Single-Use Bronchoscope

Retrieved on: 
Wednesday, December 6, 2023
Medical Supplies, Health, Medical Devices, Hospitals, Surgery, Practice Management, Health Insurance, Safety, Anesthesia, TPT, Patient, Multimedia, Airway management, CMS, Lung cancer, Diagnosis, Medicare, Reactive airway disease, Market access, Physician, Ambu, Inc., Medical device

Ambu Inc. announced today that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted the company’s aScope 5 Broncho HD a transitional pass-through (TPT) payment.

Key Points: 
  • Ambu Inc. announced today that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted the company’s aScope 5 Broncho HD a transitional pass-through (TPT) payment.
  • View the full release here: https://www.businesswire.com/news/home/20231206904736/en/
    The U.S. Centers for Medicare & Medicaid Services (CMS) has granted Ambu’s aScope 5 Broncho HD a transitional pass-through (TPT) payment.
  • The aScope 5 Broncho HD is a best-in-class single-use bronchoscopy system with high-performance functionality and imaging, combined with single-use’s distinct productivity and safety advantages.
  • TPT was granted to the aScope 5 Broncho HD series because it fit CMS criteria, which included demonstrating a substantial clinical improvement over existing single-use and reusable bronchoscopy technology.

Moligo Technologies and Nationwide Children's Hospital Collaborate to Advance Cystic Fibrosis Research Using Ultrapure Long Single-Stranded DNA

Retrieved on: 
Tuesday, October 24, 2023
Sequence, Sale, DNA, AAV, Vaidyanathan, CFTR, Research, Reactive airway disease, Risk, Crownsville Hospital Center, Gene, Cystic fibrosis, Nationwide Children's Hospital, Patient, Hospital, CF, B cell, Cystic fibrosis transmembrane conductance regulator, Vaccine

STOCKHOLM, Oct. 24, 2023 /PRNewswire/ -- Moligo Technologies announced today that it has signed a collaboration agreement with Nationwide Children's Hospital to provide long, single-stranded DNA for its research into gene therapies for cystic fibrosis (CF) and other airway diseases. Moligo's patent-pending enzymatic DNA production technology delivers ultrapure, long ssDDNA at industrial sale - with the ability to introduce chemical modifications - making it potentially suited as a non-viral delivery method in cell and gene therapies.

Key Points: 
  • STOCKHOLM, Oct. 24, 2023 /PRNewswire/ -- Moligo Technologies announced today that it has signed a collaboration agreement with Nationwide Children's Hospital to provide long, single-stranded DNA for its research into gene therapies for cystic fibrosis (CF) and other airway diseases.
  • While significant advances have been made in gene therapy, using the approach for airway diseases is still in the early stages.
  • Moligo utilizes a proprietary, PCR-free, enzymatic technology to produce ultrapure DNA strands over 10,000 bases long, 100 percent sequence-verified, and at scale.
  • Sequence complexity is also a significant challenge, making encoding many complete and functional long therapeutic genes into ssDNA impossible.

ReAlta Life Sciences Announces Poster Presentation at the European Respiratory Society 2023 International Congress

Retrieved on: 
Tuesday, September 5, 2023
Research, Infectious Diseases, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, European Respiratory Society, Human, Protocol, Reactive airway disease, Toxicology, Hypoxia (medical), Medical research, Immune system, Fraunhofer Society, Rare, International Congress on Tuberculosis, POM, White lung, Pharmaceutical industry

ReAlta Life Sciences (“ReAlta”), Inc., a clinical-stage biotech company addressing life-threatening rare diseases through harnessing the power of the immune system, today announced that it will be presenting additional clinical data from its Phase 1b trial in healthy volunteers on RLS-0071 at the European Respiratory Society 2023 International Congress taking place in Milan, Italy on 9-13 September, 2023.

Key Points: 
  • ReAlta Life Sciences (“ReAlta”), Inc., a clinical-stage biotech company addressing life-threatening rare diseases through harnessing the power of the immune system, today announced that it will be presenting additional clinical data from its Phase 1b trial in healthy volunteers on RLS-0071 at the European Respiratory Society 2023 International Congress taking place in Milan, Italy on 9-13 September, 2023.
  • RLS-0071, the Company’s complement inhibitor and innate anti-inflammatory product candidate, is being developed as a treatment for hypoxic ischemic encephalopathy and other acute inflammatory and rare diseases.
  • The new data will be presented by Prof. Dr. Jens M. Hohlfeld, Division Director of Airway Research at the Fraunhofer Institute for Toxicology and Experimental Medicine (Hannover, Germany) and lead investigator on the Phase 1b trial.
  • Session 68 (PA608) – From bench to bedside: translational studies in airway diseases

RSNA: Smaller Lung Airways May Increase COPD Risk in Women

Retrieved on: 
Tuesday, August 2, 2022
Linda, Radiation, Division, RSNA, Diagnosis, Smoker, University, Radiological Society of North America, Education, A Call for Unity, Tobacco, Mortality, Urbanization, Sex, Respiratory disease, Health, Woman, Trachea, Reactive airway disease, Smoking, Research, Radiology, Thorax, OAK, Chronic obstructive pulmonary disease, Risk, Medicine, University of Wisconsin School of Medicine and Public Health, Body mass index, Genetic epidemiology, Society, Trial of the century, Doctor of Philosophy, Breathe Me, Survival, Man, COPD, Birmingham, Association, Korea Disease Control and Prevention Agency, Growth, Degenerative disease, Center, Lung, Critical Care Medicine (journal), Public health, Prevalence, Birth control, Life insurance, Pharmaceutical industry, Airline, Medical imaging

OAK BROOK, Ill., Aug. 2, 2022 /PRNewswire-PRWeb/ -- Structural differences in lung airways between men and woman may be the cause of differences in chronic obstructive pulmonary disease (COPD) prevalence and outcomes between the sexes. According to a large, multicenter study published in the journal Radiology, researchers found that even among adults who have never smoked, or who have smoked less than 100 cigarettes in their lifetime, lung airways were smaller in women, which can lead to a higher risk for lung disease.

Key Points: 
  • According to a large, multicenter study published in the journal Radiology, researchers found that even among adults who have never smoked, or who have smoked less than 100 cigarettes in their lifetime, lung airways were smaller in women, which can lead to a higher risk for lung disease.
  • According to a large, multicenter study published in the journal Radiology , researchers found that even among adults who have never smoked, or who have smoked less than 100 cigarettes in their lifetime, lung airways were smaller in women, which can lead to a higher risk for lung disease.
  • "When airways narrow due to cigarette smoking, the impact on symptoms and survival is greater in women than in men."
  • The assumption that women have smaller airways is based on comparisons of the trachea and main stem bronchi, but few studies have compared distal airways in normal individuals or accounted for differences in lung size.

EpiEndo: Successful Completion of Phase I Study for Lead Asset EP395

Retrieved on: 
Wednesday, May 18, 2022
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Phases of clinical research, Inflammation, Pharmacology, Patient, ClinicalTrials.gov, Phase, Pharmacokinetics, Reactive airway disease, Epithelium, Principal, University, Safety, Biomarker, Chronic obstructive pulmonary disease, Drug development, Lung, Therapy, Skin, Chronic Respiratory Disease, Pharmaceutical industry, Vaccine, COPD

EpiEndo will begin Phase Ib and Phase IIa studies with EP395 later this year, with top-level data to become available during 2023.

Key Points: 
  • EpiEndo will begin Phase Ib and Phase IIa studies with EP395 later this year, with top-level data to become available during 2023.
  • The Phase Ib study will be a proof of pharmacology study in healthy volunteers.
  • The Phase IIa study will assess the safety and tolerability of EP395 in patients with COPD, as well as assessing biomarkers for anti-inflammatory efficacy.
  • EpiEndos lead drug candidate, EP395, aims to be the first on-market oral, non-antibiotic, barrier strengthening and anti-inflammatory macrolide for the treatment of COPD.

Global Reactive Airway Disease Market to 2032 - Insight, Epidemiology and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, May 16, 2022
Health, Pharmaceutical, Report, Reactive airway disease, SWOT, Disease, Epidemiology, Porter's five forces analysis, Growth–share matrix, Review, Competition, Research, Lists of people executed in the United States, PESTLE, Awareness, Organizing, SME, Diagnosis, Airline, Pharmaceutical industry

The "Reactive Airway Disease - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Reactive Airway Disease - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's offering.
  • This report delivers an in-depth understanding of the Reactive Airway Disease, historical and forecasted epidemiology as well as the Reactive Airway Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The Reactive Airway Disease market report provides current treatment practices, emerging drugs, Reactive Airway Disease market share of the individual therapies, current and forecasted Reactive Airway Disease market Size from 2019 to 2032 segmented by seven major markets.
  • The Report also covers current Reactive Airway Disease treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

VIDA Introduces New AI-Enabled Biomarker Services

Retrieved on: 
Sunday, May 15, 2022
Physician, Risk, National identity cards in the European Economic Area, Ventilation, TAC, International Conference on Information Systems Security and Privacy, Asthma, Chief Medical Advisor to the President, Respiratory disease, CACS, Degenerative disease, Patient, Multimedia, COPD, Lung cancer, American Thoracic Society, Bronchiectasis, Data, COVID-19, TGA, Methylenedioxypyrovalerone, Reactive airway disease, VIDA, FDA, SAN, CAC, Interstitial lung disease, Conference, ATS, Atmosphere, Biomarker, PMDA, Respiration, Drug development, Lung, Chronic obstructive pulmonary disease, Health Canada, LinkedIn, Twitter, Intelligence, MD, Medical device, Medical imaging, Arthur Agatston

SAN FRANCISCO, May 15, 2022 /PRNewswire/ -- (ATS International Conference) — VIDA Diagnostics, Inc. (VIDA), the leader in lung and respiratory intelligence data, is introducing a new suite of retrospective data analysis services for clinical trial sponsors in response to growing demand for precision data to optimize lung treatment trials. Announced at the 2022 American Thoracic Society (ATS) International Conference, this suite of services empowers sponsors to leverage VIDA's unique AI-enabled biomarker generation services and decades of validated techniques with previously generated imaging cohorts.

Key Points: 
  • Announced at the 2022 American Thoracic Society (ATS) International Conference, this suite of services empowers sponsors to leverage VIDA's unique AI-enabled biomarker generation services and decades of validated techniques with previously generated imaging cohorts.
  • VIDA's retrospective data analysis services are used to uncover new insights about therapeutic mechanisms of action and/or characteristics of a responder population.
  • In addition, VIDA is continuously innovating through partnerships with pulmonary leaders to advance new multi-modality imaging biomarkers."
  • VIDA is also announcing a new vascular biomarker: coronary artery calcium score (CACS) providing a cumulative Agatston score which is a measure of coronary artery calcification.

Cystic Fibrosis Foundation Announces Steven Rowe, MD, as Next Chief Scientific Officer

Retrieved on: 
Wednesday, January 26, 2022
Research, General Health, Professional Services, Philanthropy, Pharmaceutical, Infectious Diseases, Genetics, Foundation, Clinical Trials, Science, Biotechnology, Human Resources, Health, University, Cystic fibrosis transmembrane conductance regulator, Cystic Fibrosis Foundation, Valencia CF Foundation, National, CFTR, University of Alabama, Diabetes, GI, Conditional sentence, Path, Investment, Cystic fibrosis, Multimedia, Reactive airway disease, Research, Biology, Mucus, UAB, CSO, Method, MD, Allergy, Disease, CEO, Mark (given name), Pharmaceutical industry, Vaccine, Elexacaftor/tezacaftor/ivacaftor, Foundation

Today, the Cystic Fibrosis Foundation announced that Steven Rowe, MD, will be its next chief scientific officer.

Key Points: 
  • Today, the Cystic Fibrosis Foundation announced that Steven Rowe, MD, will be its next chief scientific officer.
  • In this role, Dr. Rowe will oversee the Foundations basic science, academic research, and venture philanthropy program investments, which include the CF Foundation Lab and the Path to a Cure initiative.
  • The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis.
  • The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support.

Cartesian Therapeutics Adds Five Internationally Recognized Experts to Board of Advisors

Retrieved on: 
Tuesday, December 14, 2021
Therapy, National academy, Senior advisor, Mallinckrodt, RNA, NIH, Pathology, Brigham and Women's Hospital, Physician, Respiratory disease, Hospital, Cone Health Women's Hospital, Intensive care unit, Harvard Medical School, Proning, COVID-19, Autoimmunity, Virginia School for Girls, GMG, Sepsis, UCSF, Stem cell, Degenerative disease, Pulmonary edema, Research, Reactive airway disease, Biotechnology, Inflammation, CGMP, Medical laboratory, Pediatric intensive care unit, Drug development, Associate, Infection, Department, San Francisco, Neurology, Natural history, University, Atherosclerosis, University of Virginia School of Medicine, National Academy of Medicine, Pharmaceutical industry, Management, Cartesian, Medicine, Anesthesia, MD

Cartesian's new appointments include distinguished physicians, scientists, professors, and industry experts lauded as leaders in drug development and medicine.

Key Points: 
  • Cartesian's new appointments include distinguished physicians, scientists, professors, and industry experts lauded as leaders in drug development and medicine.
  • "Cartesian is proud to have these prestigious, multidisciplinary advisors dedicated to advancing our mission," said MiloMiljkovi, M.D., Chief Medical Officer at Cartesian Therapeutics.
  • "Their perspectives will provide the utmost value in supporting the continued advancement of our clinical pipeline."
  • Founded in 2016 and with three assets in clinical trials, Cartesian is the leader in RNA cell therapy.

BELLUS Health to Report Additional RELIEF Data in an Oral Presentation at the European Respiratory Society International Congress 2021

Retrieved on: 
Monday, August 23, 2021
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Company, Reactive airway disease, Population, Quality of life, Legislation, Risk factor, Pain, ERS, Therapy, Burn, U.S. Securities and Exchange Commission, Life, Intention, International, Chronic cough, BLU, RCC, Nasdaq, Private Securities Litigation Reform Act, Health, Time, Forward-looking statement, Cough, European Respiratory Society, Risk, Achievement, Sensation, News, Patient, Environment, AD, Itch, Irritation, TSX, Disorder, Annual report, COVID-19, Pharmaceutical industry, BLU-5937, BELLUS Health (, BLU-5937, BELLUS HEALTH (

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (BELLUS Health or the Company), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (RCC) and other hypersensitization-related disorders, today announced that an abstract covering additional data from the RELIEF Phase 2a trial has been accepted for oral presentation at the upcoming European Respiratory Society (ERS) International Congress 2021, being held September 5-8, 2021.

Key Points: 
  • BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (BELLUS Health or the Company), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (RCC) and other hypersensitization-related disorders, today announced that an abstract covering additional data from the RELIEF Phase 2a trial has been accepted for oral presentation at the upcoming European Respiratory Society (ERS) International Congress 2021, being held September 5-8, 2021.
  • Session: Clinical trials in airway diseases: novel treatments and new evidence
    For more information and to access the pre-recorded presentation, please visit the ERS congress platform .
  • Following the conference, the presentation materials will be available in the Scientific Publications section of BELLUS Health's website at www.bellushealth.com .
  • BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of RCC and other hypersensitization-related disorders.